Investigational drug · Phase 2
ACE1831
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for IgG4 Related Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ACE1831"
First trial start
2026
Jan 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ACE1831", any sponsor or status.
Conditions studied
As listed on its trial records.
- IgG4 Related Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ACE1831" as an intervention, largest first.
- Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related DiseaseActive, not recruiting
Acepodia Biotech, Inc.Industry
NCT07061938 · 34 participants (planned) · Start Jan 1, 2026 · Primary completion Sep 20, 2029
Drug: ACE1831; Lymphodepleting chemotherapy · For: IgG4 Related Disease
Sites: Atlanta, Georgia; Boston, Massachusetts; Beijing, China · 11 sites in all
- ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (SLE)Not yet recruiting
Tongji HospitalAcademic, hospital or other
NCT07314567 · 22 participants (planned) · Start Jan 1, 2026 · Primary completion Oct 30, 2027
Drug: ACE1831; Lymphodepleting chemotherapy · For: System Lupus Erythematosus(SLE)
Sites: Wuhan, China
Acepodia Biotech, Inc.Industry
NCT05653271 · 16 participants · Start Jan 21, 2023 · Primary completion Mar 31, 2026
Drug: Cyclophosphamide; Fludarabine and 2 more · For: B-cell Lymphoma; Non Hodgkin Lymphoma; DLBCL and 5 more
Sites: Orlando, Florida; Atlanta, Georgia; Indianapolis, Indiana · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Lymphoma.
Li HK, Wu TS, Kuo YC, et al. · Cancers (Basel) 2023
Also in development for IgG4 Related Disease
- ObexelimabPhase 34 trials
Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.